Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AFFiRiS AG logo — Novel disease-modifying therapies for neurodegenerative dise...

AFFiRiS AG

Novel disease-modifying therapies for neurodegenerative diseases. From brains for brains. From us for you.

Founded 2003 Austria Austria 2 employees Total: $47.00M Biotechnology, Pharmaceutical

General Information

Company Name AFFiRiS AG
Founded Year 2003
Location Austria Austria
Employees 2
Industries Biotechnology, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with AFFiRiS AG. To contact AFFiRiS AG, visit affiris.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AFFiRiS AG compare?

A PDF of AFFiRiS AG and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AFFiRiS AG soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AFFiRiS AG

AFFiRiS AG is a clinical-stage biotechnology company based in Austria, founded in 2003. The company's slogan, "Novel disease-modifying therapies for neurodegenerative diseases. From brains for brains. From us for you," encapsulates their mission to challenge established treatment options for neurodegenerative diseases and preserve the quality of life of patients. With a focus on unmet medical needs in chronic diseases, AFFiRiS aims to develop therapeutic and preventative treatments inspired by the impact of vaccines on health and society worldwide. The company's novel approach, Specific Active ImmunoTherapy (SAIT), is developed using their AFFITOME technology, which allows for the optimization of immune responses against pathogenic forms of proteins. This approach stimulates the body's own immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. Their pipeline includes a broad portfolio of immunotherapy candidates, currently in clinical trials or preclinical development for chronic diseases such as Parkinson's Disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and Huntington's disease. In April 2017, AFFiRiS secured a noteworthy €10.00M Venture Round investment from MIG AG. The company boasts a passionate and dedicated team with a proven track record of making ground-breaking scientific discoveries and developing novel therapies. As they continue to translate their science into clinical development, they aim to provide patients with healthier, happier, and longer lives. For more information, readers can follow AFFiRiS AG on LinkedIn and visit their website at www.affiris.com.

Business keywords: Immunotherapy, Neurodegenerative Diseases, Parkinson's Disease, Alzheimer's Disease, Multiple System Atrophy, Dementia with Lewy Bodies, Huntington's Disease, Clinical-stage Biotechnology, SAIT, AFFITOME Technology, Peptide Vaccines, Vienna, Austria, Clinical Trials, Monoclonal Antibody

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC €10.00M -
01 Apr 2017
Late VC €10.00M 2
MIG Capital
MIG Capital, Santo Venture Capital
01 Jun 2016
Early VC €2.00M -
01 Dec 2012
Early VC €25.00M 2
MIG Capital
MIG Capital, Santo Venture Capital
01 Nov 2011

AFFiRiS AG Alternatives & Competitors

View All Alternatives
AFFiRiS AG vs
AC Immune
AC Immune Switzerland

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease...

Post-IPO Equity
179 employees
Biotechnology, Health and Wellness
Compare AFFiRiS AG vs AC Immune
AFFiRiS AG vs
Athira Pharma
Athira Pharma United States

Restoring lives by advancing bold therapies for neuronal health, thoughtfully and urgently

Post-IPO Equity
46 employees
Biotechnology, Health and Wellness
Compare AFFiRiS AG vs Athira Pharma
AFFiRiS AG vs
Vaxxinity
Vaxxinity United States

Our mission is to democratize health by pioneering the third biologic revolution

Grant
44 employees
Biotechnology, Pharmaceutical
Compare AFFiRiS AG vs Vaxxinity
Also compare with: AFFiRiS AG vs Alector Alector View all alternatives

FAQ About AFFiRiS AG

Novel disease-modifying therapies for neurodegenerative diseases. From brains for brains. From us for you.
AFFiRiS AG was founded in 2003.
AFFiRiS AG is headquartered in Austria.
AFFiRiS AG operates in Biotechnology and Pharmaceutical. Its work centres on Immunotherapy, Neurodegenerative Diseases, Parkinson's Disease and Alzheimer's Disease.
AFFiRiS AG has approximately 2 employees.
AFFiRiS AG has completed 4 funding rounds, raising a total of $47.00M.
Top alternatives and competitors to AFFiRiS AG include AC Immune, Athira Pharma, Vaxxinity, Cognition Therapeutics, Inc., Alector. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AFFiRiS AG and AC Immune are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AFFiRiS AG, https://www.bouncewatch.com/company/affiris-ag, updated 28 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout